Empowering Breast Surgeons: A Call for Collective Action
As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.
Related Articles
Endometrial Cancer Classification and Management in the Molecular Subtyping Era
A 65-year-old woman presented with a 6-month history of postmenopausal vaginal bleeding, and endometrial biopsy showed grade 2 endometrioid adenocarcinoma. What would you do next?
New Developments in CAR T Treatments Webinar Infographic Series
The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured…
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year…
What’s new in breast cancer research? SABCS24 looks at ctDNA, AI and ‘right-sizing’ treatment
More than 11,000 researchers, clinicians, patient advocates and drugmakers gathered last week at the San Antonio Breast Cancer Symposium to share the latest treatments, tricks…
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.
Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma
Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.
Selpercatinib Treatment Beyond Progression in RET Fusion–Positive Non–Small Cell Lung Cancer | JCO Oncology Advances
PURPOSESelpercatinib, a highly selective RET kinase inhibitor with CNS activity, is approved in multiple countries for patients with RET fusion–positive non–small cell lung cancer (NSCLC).METHODSPatients…
Cardiac Events and Survival in EGFR-Mutant NSCLC Treated With Osimertinib
This cohort study examines whether osimertinib is associated with a higher incidence of cardiac toxic effects compared with earlier-generation epidermal growth factor receptor tyrosine kinase…
Improved risk stratification of SMM using trajectory data in the PANGEA 2.0 model
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the new PANGEA 2.0 model, which aims to improve risk stratification of smoldering multiple myeloma (SMM)…
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.